Biomea Fusion Inc (BMEA)

Biomea Fusion's stock price has significantly declined over the past year. Citigroup maintained a "Buy" recommendation, while JPMorgan downgraded Biomea Fusion to "Underweight". D. Boral Capital lowered its price target. The company reported its Third Quarter 2025 financial results, showcasing preclinical advances for BMF-650 and icovamenib. Jefferies initiated coverage of Biomea Fusion with a "Buy" recommendation. The company advanced its diabetes and obesity programs, with icovamenib demonstrating durable 52-week Phase II data and BMF-650 dosing its first patient in a Phase I clinical trial.

Information directly addressing demand seasonality for Biomea Fusion, Inc.'s specific products and services is not readily available. As a clinical-stage biopharmaceutical company, its revenue generation is primarily tied to research and development milestones and potential future commercialization.

Biomea Fusion, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing oral covalent small molecule drugs for genetically defined cancers and metabolic disorders like diabetes and obesity. Its major product candidates include Icovamenib (BMF-219), an orally bioavailable menin inhibitor for Type 1 and Type 2 diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist for obesity.

Biomea Fusion, Inc. is headquartered in San Carlos, California, United States, and was founded in 2017. While its operations are based in the U.S., the company's focus on metabolic disorders addresses a global health challenge.

Biomea Fusion has actively participated in investor conferences and presented preclinical data, contributing positively to its reputation. Positive results from the Phase II COVALENT-111 study of icovamenib are also positive. However, the significant decline in its stock price and a downgrade by JPMorgan could reflect challenges or shifts in investor sentiment.

Biomea Fusion, Inc. has a diverse ownership structure, including institutional, insider, and retail investors. Major institutional owners include Fmr Llc, Cormorant Asset Management, LP, and Vanguard Group Inc. The largest individual shareholder is Thomas Andrew Butler.